MCL1 and glioblastoma: Across different freshly resected IDHwt GBM samples, we found that targeting both MCL-1 and BCL-xL led to an extensive induction of apoptosis and sustained reduction in tumour cell viability ex vivo, without compromising tissue and vessel integrity.